Caracterização farmacoepidemiológica de indivíduos com doença de Parkinson para implantação de serviço clínico farmacêutico

Abstract

Parkinson's disease is a neurodegenerative disease that usually leads to severe disability after 10 to 15 years and represents high social and financial impacts, particularly in the older population. Few studies contemplate its pharmacoepidemiologic complexity. Thus, the aim of this article was to describe the pharmacoepidemiological profile of the patients, aiming to support the proposition of a clinical pharmacist service. This is a cross-sectional study with 70 Parkinson Disease patients registered in the Specialized Component of Pharmaceutical Assistance in Florianópolis, which began pharmacotherapeutic follow-up on October 2012. Data collection was performed in the first pharmaceutical consultation. Data were collected in Data were collected in a specific form mixing the Pharmacotherapy Workup and Dáder. Sociodemographic, clinical and pharmacological data were analysed. Of the 70 patients, 64.3 % were men, with a middle age of 69.4 years (standard deviation =11 years), with cognitive deficit, 37.1 % needed a caregiver and only 22.9 % had all the health care needs covered by the SUS. The quality of life presented affected by motor symptoms and dysautonomias. All patients were polymedicated with an average of 6.8 medicines for patients (standard deviation = 3.1 medicines), and 60% and 53% of patients were not adherent to treatment, according Moriski and pharmaceutical consultation, respectively. Based on pharmacoepidemiological profile it is possible to realize the importance of a clinical pharmacy service directed to these patients covering all their needs related to pharmacotherapy, contributing to improve the quality of life, with clinical and humanistic outcomes more satisfactory. Key words: Pharmaceutical Care, Parkinson disease, Unified Health System.